Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
8.51
+0.95 (12.57%)
Dec 16, 2025, 3:08 PM EST - Market open
Verrica Pharmaceuticals Employees
Verrica Pharmaceuticals had 71 employees as of December 31, 2024. The number of employees decreased by 29 or -29.00% compared to the previous year.
Employees
71
Change (1Y)
-29
Growth (1Y)
-29.00%
Revenue / Employee
$434,211
Profits / Employee
-$366,394
Market Cap
136.07M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 71 | -29 | -29.00% |
| Dec 31, 2023 | 100 | 78 | 354.55% |
| Dec 31, 2022 | 22 | -16 | -42.11% |
| Dec 31, 2021 | 38 | 9 | 31.03% |
| Dec 31, 2020 | 29 | 12 | 70.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VRCA News
- 22 days ago - Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway - GlobeNewsWire
- 4 weeks ago - Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 7 weeks ago - Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 2 months ago - Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 3 months ago - Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum - GlobeNewsWire